Potent CSF-1R inhibitor
Pexidartinib is a potent colony-stimulating factor-1 receptor (CSF-1R) tyrosine kinase inhibitor (IC50 = 20 nM). In the B16F10 mouse melanoma model, Pexidartinib reduces the systemic and local accumulation of macrophages without affecting Gr-1+ myeloid derived suppressor cells. When combined with tumor-specific CD8 T cell immunotherapy, Pexidartinib promotes the control of tumor growth. In the BRAFV600E-driven mouse melanoma model, Pexidartinib improves the efficacy of adoptive cell therapy with reduction of TIMs and an increase in tumor-infiltrating lymphocytes and T cells. Orally bioavailable.
| Marque | Tocris Bioscience |
|---|---|
| Réf. B-LABO | BL-RE-125826 |
| Réf. fabricant | 18706716 |
| Nom chimique ou matériau | N-[5-[(5-Chloro-1 H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-2-pyridinyl]-6-(trifluoromethyl)-3-pyridinemethanamine |
| CAS | 1029044-16-3 |
| Quantité | 50 mg |
| Cible | Additional RTK Inhibitors |
| Formule moléculaire | C<sub>20</sub>H<sub>15</sub>ClF<sub>3</sub>N<sub>5</sub> |
| Pureté | 98% |
